Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia

Luis Miguel Veiga Veiga Nobre,Salvatore Federico Pedicona,Arran Dokal,Andrea Arruda,Ryan Smith,Calum Greenhalgh,Francesca Patella,Pedro Casado-Izquierdo,Bela Wrench,Jane Theaker,Andrew Thompson,Mark D. Minden,John G. Gribben,David James Britton,Pedro Cutillas

Blood（2021）

引用 0|浏览8

暂无评分

摘要

Background: Midostaurin is approved for FLT3 mutant-positive (FLT3+) acute myeloid leukemia (AML), however efficacy has also been observed in a subpopulation of FLT3 mutant-negative AML, suggesting that FLT3 mutation is not the only determinant conferring midostaurin sensitivity.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要